BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer

Core Insights - BioNTech SE has appointed Ramón Zapata-Gomez as Chief Financial Officer (CFO) effective July 1, 2025, succeeding Jens Holstein who will retire on June 30, 2025 [1][2][3] Company Leadership Transition - Ramón Zapata will focus on aligning BioNTech's financial direction with its strategy to become a multi-product company in oncology, optimizing financial infrastructure and performance in key markets [2][3] - Jens Holstein expressed gratitude for his tenure and highlighted BioNTech's growth into a leading global biotechnology company [3] Ramón Zapata's Background - Ramón Zapata brings over 25 years of experience in the pharmaceutical and consumer goods industries, having held leadership roles at Novartis AG, Sandoz AG, and Mondelēz International [3][4] - He has a strong track record in finance functions, overseeing M&A transactions, and driving digital finance transformations [3] BioNTech Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and other serious diseases, with a diverse portfolio of oncology product candidates [5][6] - The company is leveraging its expertise in mRNA development and manufacturing capabilities to research and develop multiple mRNA vaccine candidates for infectious diseases alongside its oncology pipeline [5]